Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: Is the risk of lethal infections too high?

European Journal of Cancer

Volumn 43, Issue 17, 2007, Pages 2532-2536

  te Poele, Esther M ^a   de Bont, Eveline S J M ^a   Marike Boezen, H ^b   Revesz, Tom ^c,f   Bökkerink, Jos P M ^d,f   Beishuizen, Auke ^e,f   Nijhuis, Ilse J M ^a,g   Oude Nijhuis, Claudi S M ^a   Veerman, Anjo J P ^f,h   Kamps, Willem A ^a,f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^g Wilhelmina Ziekenhuis   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute lymphoblastic leukaemia; All child; Corticosteroids; Dexamethasone; Glucocorticoids; Infection

Indexed keywords

ANTIBIOTIC AGENT; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; HYPOTENSION; INCIDENCE; INFECTION; INFECTION RISK; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; HUMANS; MALE; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 36148956610     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.002     Document Type: Article

References (27)

1. Slats A.M., Egeler R.M., van der Does-van den B., et al. Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 19 (2005) 537-544
2. Ito C., Evans W.E., McNinch L., et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14 (1996) 2370-2376
3. Kaspers G.J., Veerman A.J., Popp-Snijders C., et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27 (1996) 114-121
4. Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., and Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5 (1987) 202-207
5. Jones B., Freeman A.I., Shuster J.J., et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19 (1991) 269-275
6. Veerman A.J., Hahlen K., Kamps W.A., et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 (1996) 911-918
7. Bostrom B.C., Sensel M.R., Sather H.N., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
8. Mitchell C.D., Richards S.M., Kinsey S.E., Lilleyman J., Vora A., and Eden T.O. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129 (2005) 734-745
9. Steward P.M. The adrenal cortex. In: Larsen P.R., Kronenberg H.M., Melmed S., and Polonsky S.K. (Eds). Williams textbook of endocrinology. 10th ed. (2003), Saunders, Philadelphia 491-551
10. Hurwitz C.A., Silverman L.B., Schorin M.A., et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88 (2000) 1964-1969
11. Belgaumi A.F., Al Bakrah M., Al Mahr M., et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 97 (2003) 2898-2903
12. Kamps W.A., Bokkerink J.P., Hahlen K., et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 94 (1999) 1226-1236
13. Kamps W.A., Bokkerink J.P., Hakvoort-Cammel F.G., et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 16 (2002) 1099-1111
14. Veerman A.J., Hahlen K., Kamps W.A., et al. Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988). Haematol Blood Transfus 33 (1990) 473-477
15. Hettmannsperger U., Detmar M., Owsianowski M., Tenorio S., Kammler H.J., and Orfanos C.E. Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6 - inhibition by hydrocortisone, dexamethasone, and calcitriol. J Invest Dermatol 99 (1992) 531-536
16. Nyhlen K., Linden M., Andersson R., and Uppugunduri S. Corticosteroids and interferons inhibit cytokine-induced production of IL-8 by human endothelial cells. Cytokine 12 (2000) 355-360
17. Waage A., and Bakke O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 63 (1988) 299-302
18. Waage A., Slupphaug G., and Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 20 (1990) 2439-2443
19. Davis L.G. Glucocorticoid sensitivity of vasopressin mRNA levels in the paraventricular nucleus of the rat. PNAS 83 (1986) 1145-1149
20. Eberwine J.H. Complex transcriptional regulation by glucocorticoids and corticotropin-releasing hormone of proopiomelanocortin gene expression in rat pituitary cultures. DNA 6 (1987) 483-492
21. Ma X.M., and Aguilera G. Differential regulation of corticotropin-releasing hormone and vasopressin transcription by glucocorticoids. Endocrinology 140 (1999) 5642-5650
22. 2+ depletion and glucocorticoid on stimulated adrenocorticotropin release by rat anterior pituitary cells in a microperfusion system. Endocrinology 128 (1991) 1589-1596
23. Felner E.I., Thompson M.T., Ratliff A.F., White P.C., and Dickson B.A. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr 137 (2000) 21-24
24. Kuperman H., Damiani D., Chrousos G.P., et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 86 (2001) 2993-2996
25. Schlaghecke R., Kornely E., Santen R.T., and Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. New Engl J Med 326 (1992) 226-230
26. Mahachoklertwattana P., Vilaiyuk S., Hongeng S., and Okascharoen C. Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents. J Pediatr 144 (2004) 736-740
27. Rix M., Birkebaek N.H., Rosthoj S., and Clausen N. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test. J Pediatr 147 (2005) 645-650